We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.41%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$107M
(-31%)
Cap. Flow
-$82.3M
Cap. Flow
% of AUM
-33.98%
Top 10 Holdings %
Top 10 Hldgs %
35.16%
Holding
111
New
21
Increased
25
Reduced
24
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$6.87M |
| 2 |
ETNB
89bio
ETNB
|
+$5.71M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.4M |
| 4 |
Cogent Biosciences
COGT
|
+$5.12M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$10.4M |
| 3 |
Immunovant
IMVT
|
+$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$5.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.87% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Regeneron Pharmaceuticals
REGN
$77.4B
| $4.11M | 1.7% |
+5,000
| New | +$3.77M |
|
|
27
Xenon Pharmaceuticals
XENE
$6.2B
| $3.46M | 1.43% |
96,643
-157,012
| -62% | -$5.8M |
|
28
Cerus
CERS
$579M
| $3.42M | 1.41% |
1,152,902
-481,112
| -29% | -$1.45M |
|
29
Biogen
BIIB
$30.7B
| $3.14M | 1.3% |
11,311
-10,664
| -49% | -$2.95M |
|
|
ETNB
30
CALL
DELISTED
89bio
ETNB
| $3.05M | 1.26% |
+200,000
| New | +$2.61M |
|
31
Celldex Therapeutics
CLDX
$3.02B
| $3.05M | 1.26% |
84,651
+29,952
| +55% | +$1.29M |
|
32
Alnylam Pharmaceuticals
ALNY
$27.4B
| $2.81M | 1.16% |
14,043
-23,609
| -63% | -$4.96M |
|
33
Krystal Biotech
KRYS
$10.8B
| $2.72M | 1.12% |
34,014
-24,521
| -42% | -$1.93M |
|
34
Cullinan Oncology
CGEM
$1.08B
| $2.71M | 1.12% |
265,032
+35,616
| +16% | +$393K |
|
35
Pliant Therapeutics
PLRX
$65.6M
| $2.66M | 1.1% |
100,000
-117,503
| -54% | -$3.35M |
|
36
Mirum Pharmaceuticals
MIRM
$6.87B
| $2.54M | 1.05% |
+105,939
| New | +$2.41M |
|
37
Incyte
INCY
$24.9B
| $2.45M | 1.01% |
+33,938
| New | +$2.66M |
|
38
Insmed
INSM
$22B
| $2.45M | 1.01% |
143,794
+19,329
| +16% | +$376K |
|
39
Protagonist Therapeutics
PTGX
$8.92B
| $2.43M | 1% |
+105,486
| New | +$1.77M |
|
|
40
Madrigal Pharmaceuticals
MDGL
$11.4B
| $2.42M | 1% |
10,000
-39,898
| -80% | -$10.9M |
|
|
VTYX
41
DELISTED
Ventyx Biosciences
VTYX
| $2.35M | 0.97% |
+70,000
| New | +$2.72M |
|
42
MoonLake Immunotherapeutics
MLTX
$1.62B
| $2.26M | 0.93% |
+105,750
| New | +$1.78M |
|
|
MRSN
43
DELISTED
Mersana Therapeutics
MRSN
| $2.22M | 0.92% |
21,602
-24,005
| -53% | -$3.37M |
|
44
Immatics
IMTX
$1.26B
| $1.95M | 0.8% |
282,432
-157,356
| -36% | -$1.29M |
|
|
MORF
45
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.95M | 0.8% |
51,684
-282,851
| -85% | -$10.4M |
|
46
Aclaris Therapeutics
ACRS
$743M
| $1.78M | 0.74% |
220,100
-132,093
| -38% | -$1.68M |
|
47
CALL
Altimmune
ALT
$580M
| $1.75M | 0.72% |
415,700
+255,700
| +160% | +$3.04M |
|
48
Trevi Therapeutics
TRVI
$2.61B
| $1.64M | 0.68% |
885,924
+118,293
| +15% | +$268K |
|
|
RXDX
49
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $1.49M | 0.62% |
13,921
-36,079
| -72% | -$4.15M |
|
|
PNT
50
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $1.44M | 0.6% |
198,477
-202,335
| -50% | -$1.5M |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Silverarc Capital Management held 111 positions worth $242M, down 31% from $350M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Silverarc Capital Management withdrew a net $82.3M in Q1 2023, closing 39 positions and reducing 24 holdings. Its most notable exit was Immunovant, an estimated $9.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Technology.
Against the trend, Silverarc Capital Management opened a new position in 89bio worth $6.67M.
- Silverarc Capital Management's largest Q1 2023 buy was 89bio: 438,215 shares worth $6.67M.
- Silverarc Capital Management added most to Merus in Q1 2023, an estimated $6.87M increase.
- Silverarc Capital Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.9M.
- Silverarc Capital Management fully exited Immunovant in Q1 2023, selling an estimated $9.22M.
- Silverarc Capital Management's ten largest holdings make up 35% of its $242M portfolio in Q1 2023.
- Silverarc Capital Management opened 21 new positions and closed 39 in Q1 2023.
- Silverarc Capital Management's portfolio value fell 31% quarter-over-quarter to $242M.
Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.